Common Contracts

] Shares of Common Stock Pre-Funded Warrants to Purchase [ ] Shares of Common Stock and Warrants to Purchase [ ] Shares of Series A Convertible Preferred Stock Onconova Therapeutics, Inc. UNDERWRITING AGREEMENT

Underwriting Agreement • February 7th, 2018 • Onconova Therapeutics, Inc. • Pharmaceutical preparations

• Contract Type
  Underwriting Agreement
• Filed
  February 7th, 2018
• Company
  Onconova Therapeutics, Inc.
• Industry
  Pharmaceutical preparations

Onconova Therapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) an aggregate of [·] units (the “Units”) and [·] pre-funded units (“Pre-Funded Units”) representing (i) an aggregate of (a) [·] shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (“Common Stock”) and (b) pre-funded warrants to purchase [·] shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) warrants (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”) to purchase an aggregate of [·] shares of the Series A Convertible Preferred Stock, par value $0.01 per share, of the Company (“Series A Preferred Stock”). The amount and form of the Firm Securities to be purchased by the Underwriter is set forth opposite its name on Schedule I hereto. The Company also proposes to sell to the Underwriter, at the option

4,200,000 Shares FTI Consulting, Inc. Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENT

Underwriting Agreement • October 10th, 2007 • Fti Consulting Inc • Services-management consulting services • New York

• Contract Type
  Underwriting Agreement
• Filed
  October 10th, 2007
• Company
  Fti Consulting Inc
• Industry
  Services-management consulting services
• Jurisdiction
  New York

FTI Consulting, Inc., a Maryland corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives (the “Representatives”) an aggregate of 4,200,000 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 630,000 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below.